Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Bone Biologics (BBLG) Shares Outstanding (Weighted Average) (2016 - 2025)

Bone Biologics has reported Shares Outstanding (Weighted Average) over the past 3 years, most recently at $3.9 million for Q4 2017.

  • Quarterly Shares Outstanding (Weighted Average) fell 89.65% to $3.9 million in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $3.9 million through Dec 2017, down 89.65% year-over-year, with the annual reading at $38.9 million for FY2017, 3.46% up from the prior year.
  • Shares Outstanding (Weighted Average) was $3.9 million for Q4 2017 at Bone Biologics, down from $38.9 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $38.9 million in Q3 2017 and troughed at $3.9 million in Q2 2017.
  • The 3-year median for Shares Outstanding (Weighted Average) is $37.6 million (2016), against an average of $29.3 million.
  • Year-over-year, Shares Outstanding (Weighted Average) surged 32.21% in 2016 and then crashed 89.82% in 2017.
  • A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $28.5 million in 2015, then soared by 32.21% to $37.6 million in 2016, then crashed by 89.65% to $3.9 million in 2017.
  • Per Business Quant, the three most recent readings for BBLG's Shares Outstanding (Weighted Average) are $3.9 million (Q4 2017), $38.9 million (Q3 2017), and $3.9 million (Q2 2017).